Multimodality Phase II Study in Prostate Cancer

NCT00734851 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped Dose Limiting Toxicities

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Sunitinib
RADIATION: EBXRT

Sponsor

Duke University

Collaborators

[object Object]
[object Object]